Scilex Announces Nationwide Stocking And Launch Of GLOPERBA, FDA-Approved Treatment For Gout Flares In Adults
Portfolio Pulse from Benzinga Newsdesk
Scilex Holding Company has announced the nationwide stocking and launch of GLOPERBA, an FDA-approved treatment for gout flares in adults. The product is expected to be fully stocked by June 12, 2024, and is the first liquid oral formulation of colchicine for gout flare prophylaxis. Scilex has increased production and is offering a co-pay savings card for patients.
June 10, 2024 | 3:51 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Scilex Holding Company has launched GLOPERBA, an FDA-approved treatment for gout flares, nationwide. The product is expected to be fully stocked by June 12, 2024, and is the first liquid oral formulation of colchicine for gout flare prophylaxis. This launch could positively impact Scilex's stock price in the short term.
The launch of GLOPERBA, a unique FDA-approved product, is likely to boost Scilex's market presence and revenue. The nationwide stocking and the support of a co-pay savings card make it accessible to a broader patient base, which could drive sales and positively impact the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100